Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study

被引：0
|
作者：
Holsinger, Aaron L. [1 ,2 ]
Ramakrishnan, Aravind [1 ,2 ]
Storer, Barry [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Petersdorf, Stephen [1 ,2 ]
Deeig, H. Joachim [1 ,2 ]
Scott, Bart L. [1 ,2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1452
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [41] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
    List, AF
    Holmes, H
    Greenberg, PL
    Bennett, JM
    Oster, W
    BLOOD, 1999, 94 (10) : 305A - 305A
  • [42] Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
    Uchida, Toshiki
    Ogawa, Yoshiaki
    Kobayashi, Yukio
    Ishikawa, Takayuki
    Ohashi, Haruhiko
    Hata, Tomoko
    Usui, Noriko
    Taniwaki, Masafumi
    Ohnishi, Kazunori
    Akiyama, Hideki
    Ozawa, Keiya
    Ohyashiki, Kazuma
    Okamoto, Shinichiro
    Tomita, Akihiro
    Nakao, Shinji
    Tobinai, Kensei
    Ogura, Michinori
    Ando, Kiyoshi
    Hotta, Tomomitsu
    CANCER SCIENCE, 2011, 102 (09) : 1680 - 1686
  • [43] Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).
    Cashen, A. F.
    Juckett, A.
    Jumonville, A.
    Litzow, M. R.
    Flynn, P. J.
    Eckardt, J. R.
    LaPlant, B.
    Laumann, K. M.
    Erlichman, C.
    DiPersio, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
    Jacoby, Meagan A.
    Abboud, Camille N.
    Dipersio, John F.
    Cashen, Amanda F.
    Walter, Matthew J.
    Pizarro, Rigoberto De Jesus
    Uy, Geoffrey L.
    BLOOD, 2015, 126 (23)
  • [45] AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Daver, N.
    Montalban-Bravo, G.
    Jabbour, E.
    Di Nardo, C.
    Kornblau, S.
    Bose, P.
    Alvarado, Y.
    Ohanian, M.
    Borthakur, G.
    Cortes, J.
    Naqvi, K.
    Pemmaraju, N.
    Huang, X.
    Nogueras-Gonzalez, G.
    Bueso-Ramos, C.
    Gasior, Y.
    Bayer, V.
    Pierce, S.
    Yang, H.
    Colla, S.
    Kantarjian, H.
    HAEMATOLOGICA, 2017, 102 : 183 - 183
  • [46] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [47] Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Vivian
    Wei, Andrew
    Vyas, Paresh
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
    Swaminathan, Mahesh
    Kantarjian, Hagop M.
    Levis, Mark
    Guerra, Veronica
    Borthakur, Gautam
    Alvarado, Yesid
    DiNardo, Courtney D.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Daver, Naval
    Konopleva, Marina
    Pemmaraju, Naveen
    Ferrajol, Alessandra
    Andreeff, Michael
    Jain, Nitin
    Estrov, Zeev
    Jabbour, Elias J.
    Wierda, William G.
    Pierce, Sherry
    Pinsoy, Maria Rhona
    Xiao, Lianchun
    Ravandi, Farhad
    Cortes, Jorge E.
    HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130
  • [49] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Tiu, Ramon V.
    Advani, Anjali S.
    Afable, Manual
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Paquette, Ronald
    Smith, April
    Strozniak, Lori
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [50] Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy
    Duong, Vu H.
    Jaglal, Michael V.
    Zhang, Ling
    Kale, Vishakha
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 752 - 753
12345